About
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company developing novel oral therapies targeting neuropsychiatric disorders, initially focusing on trichotillomania, a condition with no approved treatments. Their technology targets System xC- to modulate glutamate signaling implicated in these disorders.
Explore Promentis Pharmaceuticals, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.